These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7285481)

  • 1. Ceforanide kinetics in renal insufficiency.
    Hawkins SS; Alford RH; Stone WJ; Smyth RD; Pfeffer M
    Clin Pharmacol Ther; 1981 Oct; 30(4):468-74. PubMed ID: 7285481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.
    Hess JR; Berman SJ; Boughton WH; Sugihara JG; Musgrave JE; Wong EG; Siemsen AM
    Antimicrob Agents Chemother; 1980 Feb; 17(2):251-3. PubMed ID: 7387145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ceforanide.
    Ripa S; La Rosa F; Ghezzi A; Prenna M; Pfeffer M
    Antimicrob Agents Chemother; 1982 Feb; 21(2):323-6. PubMed ID: 7073268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceforanide kinetics.
    Estey EH; Weaver SS; LeBlanc BM; Brown N; Ho DH; Bodey GP
    Clin Pharmacol Ther; 1981 Sep; 30(3):396-403. PubMed ID: 7273604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefamandole kinetics in uremic patients undergoing hemodialysis.
    Gambertoglio JG; Aziz NS; Lin ET; Grausz H; Naughton JL; Benet LZ
    Clin Pharmacol Ther; 1979 Nov; 26(5):592-9. PubMed ID: 498702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis.
    Barriere SL; Gambertoglio JG; Alexander DP; Stagg RJ; Conte JE
    Rev Infect Dis; 1984; 6 Suppl 4():S809-15. PubMed ID: 6522922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative tissue distribution of ceforanide, cefazolin, and cefamandole in rats.
    Lee FH; Smyth RD; Van Harken DR
    Antimicrob Agents Chemother; 1981 Apr; 19(4):625-7. PubMed ID: 7247385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents.
    Dajani AS; Thirumoorthi MC; Bawdon RE; Buckley JA; Pfeffer M; Van Harken DR; Smyth RD
    Antimicrob Agents Chemother; 1982 Feb; 21(2):282-7. PubMed ID: 7073266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biliary levels of ceforanide.
    Kenady DE; Ram MD
    Antimicrob Agents Chemother; 1983 May; 23(5):706-9. PubMed ID: 6870219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceforanide pharmacokinetics in haemodialysis: the effect of ultrafiltration.
    Lanao JM; de Prada CR; Dominguez-Gil A; Tabernero JM; Martín J; Gómez JR
    Biopharm Drug Dispos; 1986; 7(4):335-46. PubMed ID: 3768489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.
    Lee FH; Pfeffer M; Van Harken DR; Smyth RD; Hottendorf GH
    Antimicrob Agents Chemother; 1980 Feb; 17(2):188-92. PubMed ID: 7387141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.
    Brogard JM; Kopferschmitt J; Spach MO; Grudet O; Lavillaureix J
    J Clin Pharmacol; 1979 Jul; 19(7):366-77. PubMed ID: 479381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.
    Bliss M; Mayersohn M; Arnold T; Logan J; Michael UF; Jones W
    Antimicrob Agents Chemother; 1986 Apr; 29(4):649-53. PubMed ID: 3707113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penetration of ceforanide and cefamandole into the right atrial appendage, pericardial fluid, sternum, and intercostal muscle of patients undergoing open heart surgery.
    Mullany LD; French MA; Nightingale CH; Low HB; Ellison LH; Quintiliani R
    Antimicrob Agents Chemother; 1982 Mar; 21(3):416-20. PubMed ID: 7103445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide.
    Pfeffer M; Gaver RC; Van Harken DR
    J Pharm Sci; 1980 Apr; 69(4):398-403. PubMed ID: 7373533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefamandole in patients with renal impairment.
    Czerwinski AW; Pederson JA
    Antimicrob Agents Chemother; 1979 Feb; 15(2):161-4. PubMed ID: 426510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of renal dysfunction on the pharmacokinetics of loracarbef.
    Therasse DG; Farlow DS; Davidson RL; Quadracci LJ; Hatcher BL; Cerimele BJ; DeSante KA
    Clin Pharmacol Ther; 1993 Sep; 54(3):311-6. PubMed ID: 8375126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of cefamandole in patients with reduced renal function.
    Czerwinski AW; Pederson JA
    Scand J Infect Dis Suppl; 1980; suppl 25():45-8. PubMed ID: 6937951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isepamicin disposition in subjects with various degrees of renal function.
    Halstenson CE; Kelloway JS; Affrime MB; Lin CC; Teal MA; Shapiro BE; Awni WM
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2382-7. PubMed ID: 1804011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.